Susquehanna International Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.6M | Buy |
8,000
+5,200
| +186% | +$1.03M | ﹤0.01% | 6697 |
|
|
2025
Q4 | $529K | Buy |
2,800
+900
| +47% | +$173K | ﹤0.01% | 8648 |
|
|
2025
Q3 | $337K | Buy |
+1,900
| New | +$282K | ﹤0.01% | 9853 |
|
|
2024
Q3 | – | Sell |
-6,600
| Closed | -$556K | – | 12562 |
|
|
2024
Q2 | $556K | Sell |
6,600
-7,400
| -53% | -$589K | ﹤0.01% | 8001 |
|
|
2024
Q1 | $1.02M | Buy |
14,000
+1,700
| +14% | +$125K | ﹤0.01% | 6858 |
|
|
2023
Q4 | $878K | Sell |
12,300
-2,100
| -15% | -$124K | ﹤0.01% | 7309 |
|
|
2023
Q3 | $863K | Sell |
14,400
-8,900
| -38% | -$586K | ﹤0.01% | 6959 |
|
|
2023
Q2 | $1.68M | Buy |
23,300
+18,000
| +340% | +$1.35M | ﹤0.01% | 5514 |
|
|
2023
Q1 | $390K | Buy |
+5,300
| New | +$377K | ﹤0.01% | 9159 |
|
|
2022
Q4 | – | Sell |
-7,214
| Closed | -$387K | – | 13122 |
|
|
2022
Q3 | $387K | Buy |
7,214
+321
| +5% | +$18.9K | ﹤0.01% | 9139 |
|
|
2022
Q2 | $384K | Sell |
6,893
-26,930
| -80% | -$1.53M | ﹤0.01% | 8897 |
|
|
2022
Q1 | $2.37M | Buy |
33,823
+6,091
| +22% | +$442K | ﹤0.01% | 5082 |
|
|
2021
Q4 | $2.67M | Sell |
27,732
-24,686
| -47% | -$2.28M | ﹤0.01% | 4856 |
|
|
2021
Q3 | $4.56M | Sell |
52,418
-82,394
| -61% | -$6.37M | ﹤0.01% | 4124 |
|
|
2021
Q2 | $11M | Sell |
134,812
-37,350
| -22% | -$3.11M | ﹤0.01% | 2769 |
|
|
2021
Q1 | $16.4M | Sell |
172,162
-55,624
| -24% | -$5.26M | ﹤0.01% | 2128 |
|
|
2020
Q4 | $14.1M | Buy |
227,786
+121,828
| +115% | +$6.95M | ﹤0.01% | 2099 |
|
|
2020
Q3 | $6.3M | Sell |
105,958
-149,240
| -58% | -$10.2M | ﹤0.01% | 2771 |
|
|
2020
Q2 | $17.8M | Buy |
255,198
+142,186
| +126% | +$9.01M | ﹤0.01% | 1530 |
|
|
2020
Q1 | $5.13M | Buy |
113,012
+20,839
| +23% | +$1.18M | ﹤0.01% | 2538 |
|
|
2019
Q4 | $6M | Sell |
92,173
-489,876
| -84% | -$32.7M | ﹤0.01% | 2729 |
|
|
2019
Q3 | $36.1M | Sell |
582,049
-36,869
| -6% | -$2.31M | 0.01% | 932 |
|
|
2019
Q2 | $44.1M | Sell |
618,918
-51,457
| -8% | -$3.79M | 0.02% | 764 |
|
|
2019
Q1 | $52.6M | Buy |
670,375
+547,425
| +445% | +$41.5M | 0.02% | 604 |
|
|
2018
Q4 | $10.4M | Buy |
122,950
+64,120
| +109% | +$6.84M | ﹤0.01% | 1577 |
|
|
2018
Q3 | $10.1M | Sell |
58,830
-7,695
| -12% | -$1.16M | ﹤0.01% | 1924 |
|
|
2018
Q2 | $8.6M | Buy |
66,525
+321
| +0.5% | +$35.8K | ﹤0.01% | 2094 |
|
|
2018
Q1 | $6.82M | Buy |
66,204
+50,334
| +317% | +$4.98M | ﹤0.01% | 2166 |
|
|
2017
Q4 | $1.36M | Buy |
15,870
+321
| +2% | +$27.8K | ﹤0.01% | 4627 |
|
|
2017
Q3 | $1.32M | Buy |
15,549
+9,297
| +149% | +$736K | ﹤0.01% | 4731 |
|
|
2017
Q2 | $473K | Sell |
6,252
-113,973
| -95% | -$7.97M | ﹤0.01% | 6745 |
|
|
2017
Q1 | $7.94M | Sell |
120,225
-238,366
| -66% | -$15.7M | ﹤0.01% | 1856 |
|
|
2016
Q4 | $22.7M | Buy |
358,591
+249,266
| +228% | +$15.7M | 0.01% | 956 |
|
|
2016
Q3 | $6.96M | Buy |
109,325
+54,663
| +100% | +$4.01M | ﹤0.01% | 1867 |
|
|
2016
Q2 | $4.07M | Buy |
54,662
+7,373
| +16% | +$547K | ﹤0.01% | 2480 |
|
|
2016
Q1 | $3.16M | Buy |
47,289
+13,466
| +40% | +$818K | ﹤0.01% | 2979 |
|
|
2015
Q4 | $2.29M | Sell |
33,823
-40,396
| -54% | -$2.49M | ﹤0.01% | 3766 |
|
|
2015
Q3 | $3.97M | Sell |
74,219
-23,564
| -24% | -$1.43M | ﹤0.01% | 3019 |
|
|
2015
Q2 | $6.16M | Sell |
97,783
-9,939
| -9% | -$542K | ﹤0.01% | 2602 |
|
|
2015
Q1 | $5.18M | Buy |
107,722
+58,189
| +117% | +$2.23M | ﹤0.01% | 2690 |
|
|
2014
Q4 | $1.64M | Sell |
49,533
-105,958
| -68% | -$3.45M | ﹤0.01% | 4833 |
|
|
2014
Q3 | $4.56M | Sell |
155,491
-16,511
| -10% | -$548K | ﹤0.01% | 3156 |
|
|
2014
Q2 | $6.68M | Buy |
172,002
+58,349
| +51% | +$2.37M | ﹤0.01% | 2642 |
|
|
2014
Q1 | $4.77M | Buy |
113,653
+45,205
| +66% | +$1.88M | ﹤0.01% | 2954 |
|
|
2013
Q4 | $2.25M | Buy |
68,448
+39,754
| +139% | +$1.3M | ﹤0.01% | 4078 |
|
|
2013
Q3 | $775K | Buy |
+28,694
| New | +$807K | ﹤0.01% | 5721 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Susquehanna International Group's LGND Position: Q1 2026 in Review
Susquehanna International Group increased its Ligand Pharmaceuticals (LGND) stake by 24% in Q1 2026, buying an estimated $256K and bringing the position to 6,703 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #7170.
Susquehanna International Group first reported a position in LGND in Q2 2013 and has held it in 42 quarters since. The position peaked at $13.5M in Q2 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Susquehanna International Group held 6,703 shares of Ligand Pharmaceuticals worth $1.34M as of Q1 2026.
- Susquehanna International Group bought 1,294 Ligand Pharmaceuticals shares in Q1 2026, an estimated $256K.
- Ligand Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7170 holding.
- Susquehanna International Group first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
- Susquehanna International Group's Ligand Pharmaceuticals position peaked at $13.5M in Q2 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.